Exelixis and Sairopa Receive the US FDA’s IND Clearance for ADU-1805 to Treat Advanced Solid Tumors
Shots:
- The US FDA has cleared the IND application to initiate the P-I trial evaluating the safety & PK of ADU-1805 in adults with advanced solid tumors. The trial is expected to be initiated in Q2’23
- As a result of this IND clearance, Sairopa will receive $35M milestones in Q1’23. Under the terms of the Nov 2022 clinical development & option agreement, Exelixis gets an option to obtain an exclusive license globally to develop and commercialize ADU-1805 and other anti-SIRPα Abs, following the review of data from prespecified P-I studies of ADU-1805
- ADU-1805 is a mAb targeting SIRPα to block the SIRPα-CD47 checkpoint & is designed to improve the immune system’s ability to attack tumors
Ref: Exelixis | Image: Exelixis
Related News:- Exelixis Entered into an Exclusive Clinical Development Collaboration and Option Agreement with Sairopa to Develop ADU-1805 for Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
